|
|
|
|
|
Market Research Report
Controlled-release: Players, products & prospects to 2018 (Volume I)
|
Controlled-release: Players, products & prospects to 2018 (Volume I) published by Espicom Business Intelligence in June, 2009. This report consists of Pages: 126 and the price starts from US $ 1040.
Abstract
The controlled-release market was worth nearly US$21 billion globally in 2008.
The sector is dominated by the launch of oral controlled-release formulations
in key therapeutic areas such as the central nervous system, cardiovascular,
metabolic and respiratory diseases. The growth of controlled-release delivery
continues to be fuelled by line extensions helping to offset the impact of
generic erosion. We estimate there are around 60 approved controlled-release
products which will generate global sales of over US$21.5 billion in 2009,
peaking at around US$29.5 billion in 2017 as products mature and face patent
expiration leading to a decline in mature product sales to US$28.9 billion by
2018. In addition, we forecast that controlled-release products in
development from 17 key companies could generate additional sales of over
US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release technologies, possibly more than any other approved
delivery systems, have been an important tool for pharmaceutical companies to
protect their branded franchises from the ever increasing and competitive
generic market. These formulations play a critical role in establishing a
balanced portfolio of solid dosage products and may lead to enhanced efficacy
and improved patient compliance. This leads to reductions in patient costs
and extending product life-cycle management for both branded and generic
pharmaceuticals.
In the past, pharmaceutical companies have tended to develop
controlled-release formulations as immediate-release counterparts near patent
expiration. This trend is reversing and companies are developing
controlled-release formulations earlier in the product life-cycle and often
launching multiple formulations (immediate release, controlled release/
modified release, and delayed release) in parallel to expand the potential
addressable patient population and gain a significant share of competitive
market places.
This report answers key questions...
- Who will have launched novel products by 2018 and what technologies could
they be using?
- Can market leaders such as ALZA and Elan maintain their status in
controlled release in the face of growing competition?
- What obstacles must companies overcome to achieve full market potential?
- What strategies are proving most productive and for which companies?
- What will the product/company landscape look like in 2018?
This report is part of a major new 4-volume strategic analysis
Focusing on the sectors that are driving growth
- VOLUME I: CONTROLLED- RELEASE
- VOLUME II: NANOTECHNOLOGY
- VOLUME III: NUCLEIC ACID DELIVERY
- VOLUME IV: TARGETED DELIVERY
Table of Contents
EXECUTIVE SUMMARY & INTRODUCTION
- Overview of controlled-release delivery: past, present & future
- Controlled delivery profiles
- Controlled-release delivery: motivators & resistors
- Controlled-release delivery: impact on product lifecycles
CONTROLLED-RELEASE DELIVERY
- Types of controlled-release delivery used
- Activated controlled-release delivery
- Degradation controlled-release delivery
- Diffusion controlled-release delivery
- Current therapeutic application of controlled-release in drug delivery
- Leading brands that utilise controlled-release delivery
- Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading controlled-release drug delivery companies
- Partnerships & acquisitions
- Intellectual Property
THE CONTROLLED-RELEASE MARKET
- Now 2009: Approved controlled-release product sales
- Future 2018: Global controlled-release product sales and novel
controlled-release product sales
COMPETITOR ANALYSIS
- Detailed analysis of leading companies covering:
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- Competitor ratio analysis
Companies analysed:
- AlphaRx Corporation
- ALZA Corporation
- Antares Pharma, Inc.
- Biovail Corporation
- Camurus AB
- Cerulean Pharma, Inc
- Cipher Pharmaceuticals, Inc.
- Debiopharm Group
- DelSite Biotechnologies, Inc.
- Depomed, Inc.
- Durect Corporation
- Elan Corporation
- Elite Pharmaceuticals, Inc.
- Endo Pharmaceuticals, Inc.
- Ethypharm SA
- Eurand N.V.
- Flamel Technologies, Inc.
- Glycologic, Ltd
- KV Pharmaceuticals, Inc
- Labopharm, Inc.
- Lavipharm SA
- Nano Interface Technology
- OctoPlus N.V.
- Penwest Pharmaceuticals, Inc.
- SCOLR Pharma, Inc.
- Shire, Plc.
- Skinvisible, Inc.
- SkyePharma, Inc.
- Spherics Pharmaceuticals, Inc.
- Watson Pharmaceuticals, Inc.
APPENDICIES
- Global controlled release approved drug sales 2008-2018
- Global controlled release development drug sales 2008-2018
- Key controlled release delivery companies by 2015
|
 |
